Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients
Journal of Clinical Medicine · 30.11.2023 · 12 (23) · 7427
DOI: 10.3390/jcm12237427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.11.2023. Verfasst von Jia-Hong Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
Abstract (Originalsprache)
Endocan, a pro-inflammatory cytokine and pro-angiogenic factor, is a marker of endothelial dysfunction and has been proven to correlate with cardiovascular disease. In hemodialysis (HD) patients, cardiovascular disease is the major cause of mortality. Our study aimed to investigate the relationship between serum endocan and all causes of mortality in HD patients. A total of 103 patients, aged over 20 years old and undergoing HD for more than 3 months, were included and followed for 36 months. Mortality events, serum endocan, biochemical data, body mass index, systolic and diastolic blood pressure, baseline characteristics, and the use of antihypertensive and lipid-lowering drugs were recorded. In our study, a total of 26 deaths (25.2%) occurred. Hemodialysis patients with diabetes mellitus, older age, higher serum endocan, and lower creatinine and albumin levels had a higher risk of mortality. Adjusting for prognostic variables, HD patients with higher serum endocan (p = 0.010) and lower serum creatinine (p = 0.034) demonstrated significantly higher all-cause mortality. In our study, increased endocan and lower creatinine are associated with all-cause mortality in HD patients. Serum endocan levels could serve as a biomarker for a high mortality risk in HD patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
- Division of Nephrology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan.
- School of Medicine, Tzu Chi University, Hualien 97004, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
ORCID-Profile: Jia-Hong Lin, Bang-Gee Hsu, Chih-Hsien Wang, Jen-Pi Tsai
Förderung
- Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
Zitieren
APA
Lin, J. H., Hsu, B. G., Wang, C. H., & Tsai, J. P. (2023). Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients. Journal of Clinical Medicine, 12(23), 7427. https://doi.org/10.3390/jcm12237427
Vancouver
Lin JH, Hsu BG, Wang CH, Tsai JP. Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients. Journal of Clinical Medicine. 2023;12(23):7427. doi:10.3390/jcm12237427
BibTeX
@article{Lin2023,
author = {Lin, Jia-Hong and Hsu, Bang-Gee and Wang, Chih-Hsien and Tsai, Jen-Pi},
title = {Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {23},
pages = {7427},
doi = {10.3390/jcm12237427}
}
EUVIMED